Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | Director | May 11, 2023 | May 15, 2023 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| ELI LILLY & CoLLY · Entity 2794 | SVP and Pres., Lilly Bio-Meds | May 03, 2019 | May 16, 2019 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Executive Chairperson | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 11, 2023 · Filed May 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,271 |
Reported balance
After 2023-05-11 transaction · row 1
1 source rowRow 1 · 2023-05-11 · Grant · Acquired 9,808 · Balance 36,271 F1: Reflects a grant of restricted stock units that vests on May 11, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 11, 2024.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
ELI LILLY & Co
Report date May 03, 2019 · Filed May 16, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2019-05-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-05-03 · Sale · Disposed 7,077 · Balance 500 F1: This amendment is being filed solely to gain access to the filing system in order to attach the power of attorney authorization. This line item is being re-reported for this purpose. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019. F3: This transaction was executed in multiple trades at prices ranging from $116.68 to $117.46. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed solely to gain access to the filing system in order to attach the power of attorney authorization. This line item is being re-reported for this purpose.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019.
F3: This transaction was executed in multiple trades at prices ranging from $116.68 to $117.46. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Kyverna Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,741 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Tax withholding · Disposed 4,194 · Balance 66,741 F1: Represents the number of shares withheld by and surrendered to the Issuer on May 27, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock unit award for 16,634 shares that vested in full on May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by and surrendered to the Issuer on May 27, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock unit award for 16,634 shares that vested in full on May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 19,676 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0001193125-26-259529 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 Underlying: Common Stock · 19,676 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Tax withholdingCommon Stock | 4,194 | $8.59 | $36,026.46 |
DisclosureSEC source: 0001193125-26-248427 · ownership.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director · Executive Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,741 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 27, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock unit award for 16,634 shares that vested in full on May 27, 2026. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 22:00 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $8.23 | $0.00 |
DisclosureSEC source: 0001193125-26-013021 · ownership.xml · derivative · entry 3 Shaw Christi · CIK 0001702473 · Director · Executive Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2036-01-11 F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 22:00 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 24,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-013021 · ownership.xml · nonDerivative · entry 2 Shaw Christi · CIK 0001702473 · Director · Executive Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,935 F2 · shares: Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 22:00 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-013021 · ownership.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director · Executive Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,634 F1 · shares: Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083054 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2025-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:40 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 65,351 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-080459 · ownership.xml · derivative · entry 2 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,351 Underlying: Common Stock · 65,351 shares Expires 2035-05-29 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:40 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 16,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080459 · ownership.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,634 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:55 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 38,679 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000950170-25-023428 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,679 Underlying: Common Stock · 38,679 shares Expires 2035-02-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall be fully vested and exercisable on October 30, 2025, subject to the Reporting Person's continuous service to the Issuer as an advisor on and through the vesting date, inclusive. Read SEC document |
| September 16, 2024 Filed Sep 19, 2024 01:16 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 66,592 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000950170-24-107967 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,592 Underlying: Common Stock · 66,592 shares Expires 2034-09-16 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on each monthly anniversary, such that 100% of the shares subject to the option shall be fully vested and exercisable on the third anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 23,114 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0000950170-24-070793 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,114 Underlying: Common Stock · 23,114 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:15 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 39,046 | $0.00 Strike: $28.28 | $0.00 |
DisclosureSEC source: 0000950170-23-070395 · ownership.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,046 Underlying: Common Stock · 39,046 shares Expires 2033-12-13 F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:44 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 9,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000113 · wf-form4_168418343875934.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,271 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2024. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:16 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 6,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000130 · wf-form4_165273939485666.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,463 F1 · kind: Reflects a grant of restricted stock units that vests on May 12, 2023. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:59 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 1,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000087 · wf-form4_164919237101467.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,770 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:36 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000096 · wf-form4_161463815280490.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,555 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:16 UTC | Avantor, Inc. AVTR · Entity 3546 | SaleCommon Stock | 14,286 | $26.68 | $381,150.48 |
DisclosureSEC source: 0001722482-20-000176 · wf-form4_160807776567001.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,319 F1 · kind: The sale reported herein reflects the transfer of shares received upon the vesting of restricted stock units. The shares transferred were subject to a lock-up agreement entered into by the Reporting Person on November 5, 2020, in connection with a secondary offering. This transaction was permitted pursuant to an exception in the lock-up agreement for parties that did not participate in such secondary offering. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.60 to $26.73, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:54 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 11,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000063 · wf-form4_158267123298865.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,605 F1 · kind: Reflects a grant of restricted stock units that vests on February 21, 2021. Read SEC document |
| May 21, 2019 Filed May 23, 2019 23:26 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 14,286 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014597 · doc4.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,286 F1 · kind: Reflects a grant of restricted stock units that vests on May 21, 2020. Read SEC document |
| May 03, 2019 Filed May 7, 2019 18:18 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 500 | $117.99 | $58,995.00 |
DisclosureSEC source: 0000059478-19-000183 · wf-form4_155725307162586.xml · nonDerivative · entry 2 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.82 to $118.15. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2019 Filed May 7, 2019 18:18 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 7,077 | $117.08 | $828,575.16 |
DisclosureSEC source: 0000059478-19-000183 · wf-form4_155725307162586.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.68 to $117.46. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2019 Filed May 16, 2019 20:44 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 7,077 | $117.08 | $828,575.16 |
DisclosureSEC source: 0000059478-19-000189 · wf-form4a_155803944803676.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: This amendment is being filed solely to gain access to the filing system in order to attach the power of attorney authorization. This line item is being re-reported for this purpose. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $116.68 to $117.46. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000181 · wf-form4_155691382911366.xml · derivative · entry 3 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vested in two equal installments on May 1, 2018 and May 1, 2019. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 6,173 | $117.04 | $722,487.92 |
DisclosureSEC source: 0000059478-19-000181 · wf-form4_155691382911366.xml · nonDerivative · entry 2 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,577 Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000181 · wf-form4_155691382911366.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2018 Filed May 31, 2018 17:05 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 8,426 | $82.10 | $691,774.60 |
DisclosureSEC source: 0000059478-18-000159 · wf-form4_152778632353976.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 20:16 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 8,426 | $82.10 | $691,774.60 |
DisclosureSEC source: 0000059478-18-000161 · wf-form4a_152788418794578.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This amendment is being filed to add footnotes to the transaction. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 26, 2018. F1 · price: This amendment is being filed to add footnotes to the transaction. F3 · price: This transaction was executed in multiple trades at prices ranging from $81.73 to $82.10. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · derivative · entry 3 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. F2 · derivative.expiration_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,324 | $81.07 | $431,616.68 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · nonDerivative · entry 2 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 8, 2017 19:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000146 · wf-form4_149427319028934.xml · derivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. F2 · derivative.expiration_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.